Clinical-stage biotechnology company
Appears in 1 story
Licensor; retains option to develop additional RNA programs outside licensed scope
Novartis agreed to pay up to $7.8 billion for rights to Chinese biotech Abogen's mRNA therapeutics. The deal includes a $575 million upfront payment and an exclusive worldwide license to ABO2203, the first mRNA-encoded T-cell engager to reach clinical testing in autoimmune disease.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
